Commonwealth Fusion Systems

Commonwealth Fusion Systems has raised over $2 billion—more than any other private fusion company. That capital moat funds SPARC, the first net-energy tokamak expected mid-decade, built on proprietary high-temperature superconducting magnets developed at MIT. If SPARC hits Q>1, it rewrites the global energy timeline. The investor base is telling: hyperscalers and sovereign wealth funds don't write $2B checks for science projects. They see a path to ARC, the commercial follow-on plant targeting the 2030s, with a compact footprint that slashes capital cost per MW versus traditional fusion designs. CFS owns the most credible timeline in the sector, has locked up critical supply chain for HTS tape, and benefits from the DOE's Milestone-Based Fusion Development Program. When SPARC demonstrates net energy, the company will own the incumbency advantage in site selection, grid interconnection, and offtake agreements. Bear case: SPARC is a science experiment, not a power plant. Achieving net energy in a lab pulse is a world away from engineering a 24/7 commercial reactor that meets grid reliability standards, passes nuclear regulatory review, and competes with solar-plus-storage at $30/MWh. CFS has disclosed no binding offtake agreements, no site permits, and no NRC design certification timeline. The HTS magnet supply chain that CFS relies on is fragile—a single manufacturing bottleneck delays everything. The company has burned through hundreds of millions with no revenue and no near-term path to revenue. Fusion's hype cycle may peak before ARC reaches financial close; if SPARC slips past 2027, investor patience (even sovereign patience) erodes. Meanwhile, competitors like TAE Technologies, Helion, and Zap Energy are pursuing alternate confinement approaches that could leapfrog tokamak complexity with cheaper, simpler machines. CFS is the leader—but leadership in a pre-revenue industry can vanish with one missed milestone.

SPARC is a science experiment, not a power plant. Achieving net energy in a lab pulse is a world away from engineering a 24/7 commercial reactor that meets grid reliability standards, passes nuclear regulatory review, and competes with solar-plus-storage at $30/MWh. CFS has disclosed no binding offtake agreements, no site permits, and no NRC design certification timeline. The HTS magnet supply chain that CFS relies on is fragile—a single manufacturing bottleneck delays everything. The company has burned through hundreds of millions with no revenue and no near-term path to revenue. Fusion's hype cycle may peak before ARC reaches financial close; if SPARC slips past 2027, investor patience (even sovereign patience) erodes. Meanwhile, competitors like TAE Technologies, Helion, and Zap Energy are pursuing alternate confinement approaches that could leapfrog tokamak complexity with cheaper, simpler machines. CFS is the leader—but leadership in a pre-revenue industry can vanish with one missed milestone.